Market Newsdesk

New York, April 13, 2021 (GLOBE NEWSWIRE) — LiquidityBook, a leading Software-as-a-Service (SaaS)-based provider of buy- and sell-side trading solutions, announced today that Primus Capital, a growth-oriented private equity firm, has made a minority investment in the company. The capital will enable LiquidityBook to further scale its business and serve a broader array of fund managers and financial institutions through its industry-leading portfolio, order and execution management system (“POEMS”) platform.

LiquidityBook will use the funds to enhance its products in response to client demand for additional functionality that goes beyond the traditional POEMS. This initiative is already well underway, as the company manages its own proprietary FIX network, LBX Connect, and recently made two key hires to support it: Stephanie Minister as Managing Director of Connectivity Services and Sumit Kumar as Senior FIX Specialist. The additional resources will meaningfully accelerate product development efforts as demand for multitenant trading technology with a single code base continues to grow, and will support global expansion.

“LiquidityBook began as a true bootstrapped startup, and working to grow it into one of the leading providers in our space has been an incredibly gratifying experience for all of us,” said Kevin Samuel, CEO and co-founder of LiquidityBook. “Thanks to strong adoption and continued client demand, our product roadmap and plans for expansion are as ambitious as ever. We have reached an inflection point where capital funding will accelerate those plans, and we are very pleased to have identified Primus as the ideal partner. Primus has a well-established track record of helping growing companies reach the next level. We look forward to a fruitful relationship and plan to leverage their financial support and strategic guidance to deliver real efficiencies for new and existing clients.”

“In what has been a period of uncertainty for many in the industry, our growth has been a constant,” said Sean Sullivan, Chief Revenue Officer at LiquidityBook. “As the number of industry firms waking up to the limitations of legacy systems continues to increase, we are rapidly winning market share thanks to our multitenant, SaaS-based model and superior functionality. This is key validation, but it also means we need to think bigger in order to continue our trajectory. This capital infusion will allow us to build out our team, make ongoing enhancements to the LBX suite and reach new clients and prospects in new markets.”

“LiquidityBook stands out as the most innovative solution in the POEMS space, addressing the primary pain points around trading flexibility, asset class expansion, cost control and compliance,” said Ron Hess, Managing Director at Primus. “We have repeatedly heard dissatisfaction with the status quo, but apprehension around making a change given the mission-criticality of these types of systems. On the contrary, LiquidityBook’s customers rave about them as a business partner, and were universally surprised by how seamlessly the onboarding process went. The most frequent sentiment we heard was ‘I wish I had done this years ago.’”   

LiquidityBook was advised in the transaction by Innovation Advisors, a technology-focused global investment bank based in New York and London. LiquidityBook recently announced record revenues and overall client growth in 2020.

About LiquidityBook

LiquidityBook is a leading SaaS-based provider of buy- and sell-side trading solutions, including order management, portfolio management, execution management, FIX network connectivity, compliance and pre- and post-trade processing. Founded in 2005, the LiquidityBook platform is trusted by many of the industry’s most sophisticated buy- and sell-side firms globally to power their trading workflows. For more information please visit www.liquiditybook.com or contact [email protected].

About Primus Capital

Primus Capital is a growth-oriented private equity firm focused on investing in leading software, healthcare and technology-enabled services companies. Primus partners with exceptional management teams to accelerate growth, improve operating performance, and increase the value of the companies in which they invest. Primus pursues buyouts, control and minority recapitalizations, secondary share purchases and expansion financings; this flexible approach enables them to engage with business owners and design tailored investment structures to meet the particular needs of the transaction. For more information, visit https://primuscapital.com.

Sam Belden
Forefront Communications for LiquidityBook
212-320-8986
[email protected]

NORWALK, Conn., April 13, 2021 (GLOBE NEWSWIRE) — FactSet (NYSE:FDS) (NASDAQ:FDS), a global provider of integrated financial information, analytical applications, and industry-leading service, announced that ICE Liquidity Indicators™ is now available in FactSet’s Portfolio Analytics, offering investment professionals a comprehensive solution to analyze, manage and report on fund liquidity risk and optimize portfolio construction within various regulatory requirements.

ICE Liquidity Indicators, part of Intercontinental Exchange (NYSE: ICE), provides market participants with an independent assessment of liquidity risk across multiple asset classes. By using a transparent methodology, the tool assigns a liquidity score to individual securities and provides metrics, such as estimates of future trade volume capacity, projected price volatility, projected days to liquidate and projected market price impact, among others.

“Leveraging ICE Liquidity Indicators through FactSet provides portfolio-specific liquidity analytics and helps the team at Jupiter provide enhanced liquidity risk management on behalf of our clients,” said Veronica Lazenby, Chief Risk Officer at Jupiter Fund Management, plc. “Recent market moves and dislocations continue to highlight how important it is for firms and clients to manage and understand this specific kind of risk holistically for effective portfolio management, as well as for regulatory compliance.”

“Liquidity risk management has grown increasingly critical over the past year,” said Rob Robie, Executive Vice President, Global Head of Analytics and Trading, FactSet. “The ability to incorporate high-quality market data and client portfolio data directly into ICE’s liquidity model means that our clients can perform scenario and sensitivity analyses and stress tests that support dynamic portfolio construction and meet regulatory requirements across various jurisdictions.”

“A growing number of investment managers want to easily quantify their liquidity risk across normal and stressed conditions and Liquidity Indicators gives them a solution to do that,” Mark Heckert, Chief Product Officer, Fixed Income and Data Services at ICE. “Providing institutional customers with clear estimates of potential activity in the market helps demonstrate sound risk management practices and can help firms meet their regulatory requirements.”

Regulators across the world continue to raise the bar when it comes to managing liquidity risks and ensuring that market participants can meet client redemption requirements. ICE Liquidity Indicators helps clients fulfil these responsibilities and currently tracks approximately 4.6 million instruments, covering nearly all asset classes (calculated as a percentage of U.S. mutual fund assets under management using publicly reported holdings data). As more securities shift to electronic platforms, investors need strong data to better understand potential trade volumes for more infrequently traded securities.

For more information about FactSet’s risk and liquidity solutions, please visit www.factset.com/risk-analytics. For more information about ICE Liquidity Indicators, please visit https://www.theice.com/market-data/pricing-and-analytics/analytics/liquidity.

About FactSet

FactSet^® (NYSE:FDS | NASDAQ:FDS) delivers superior content, analytics, and flexible technology to help more than 153,000 users see and seize opportunity sooner. We give investment professionals the edge to outperform with informed insights, workflow solutions across the portfolio lifecycle, and industry-leading support from dedicated specialists. We’re proud to have been recognized with multiple awards for our analytical and data-driven solutions and repeatedly scored 100 by the Human Rights Campaign^® Corporate Equality Index for our LGBTQ+ inclusive policies and practices.  Subscribe to our thought leadership blog to get fresh insight delivered daily at insight.factset.com. Learn more at www.factset.com and follow us on Twitter: www.twitter.com/factset. 

FactSet
Media
Jennifer Berlin
+1 617 330 4122
[email protected]

Media & Investor Relations:         
Rima Hyder         
+1 857.265.7523         
[email protected]          

Poster Presentation Highlights the Unmet Patient Need and Medical Cost Burden Associated with Hepatitis B Infection

Healthcare Costs Associated with HBV and HIV are Approximately at Parity; HBV Carries 50-100 Times Greater Transmission Risk Compared to HIV

Pharmacoeconomic Analysis and Unmet Patient Need Strongly Support Harmonization of HBV and HIV CDC Treatment Guidelines for Sexual Assault Victims

RAMSEY, N.J. and BOCA RATON, Fla., April 13, 2021 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced a poster presentation at the 2021 Academy of Managed Care Pharmacy Virtual Annual Meeting (“AMCP”) taking place April 12-16, 2021.

“Current CDC guidelines for post-exposure prophylaxis of suspected Hepatitis B infection (“HBV”) offer no intervention for sexual assault victims with perpetrators of unknown Hepatitis B surface antigen status,” said Adam Grossman, President and Chief Executive Officer of ADMA.  “HBV is significantly more infectious than is HIV, and can be transmitted by any bodily fluid, and amounts to a roughly equivalent cost burden for the US healthcare system. Our analysis suggests that amending CDC guidelines in this at-risk population for HBV to mirror those of HIV and specifically mandating a Hepatitis B Globulin intervention like ADMA’s Nabi-HB hyperimmune, will provide a cost-effective strategy for prophylactic seroprotection of these vulnerable patients. It is our hope that lobby groups advocating on behalf of at-risk patients will leverage this analysis to convey to policymakers that failing to address this patient population, and harmonizing treatment guidelines between HIV and HBV, may have considerable clinical and cost implications for the US healthcare system.”

Details for the AMCP 2021 poster presentation are as follows:

Poster Title: Pharmacoeconomic Analysis Comparing Medical Costs for Prophylaxis of HIV and HBV Infection in Sexual Assault Patients

Author: Gruenglas, Pantello, Mond
Session Title: Poster Abstract Sessions
Session Dates: Tuesday, April 13 – Wednesday, April 14, 2021 (2:30 pm ET)
Session Location: Virtual Poster Hall
Poster No: B3   

View the presentation at the virtual 2021 AMCP Annual Meeting

About Nabi-HB^®

Nabi-HB^® is a hyperimmune globulin that is rich in antibodies to the Hepatitis B virus. Nabi-HB^® is a purified human polyclonal antibody product collected from plasma donors who have been previously vaccinated with a Hepatitis B vaccine. Nabi-HB^® is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg), prenatal exposure to infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute Hepatitis B virus infection. Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus. It is a major global health problem and can cause chronic infection and put people at high risk of death from cirrhosis and liver cancer. Nabi-HB^® has a well-documented record of long-term safety and effectiveness since its initial market introduction. Certain data and other information about Nabi-HB^® or ADMA Biologics and its products can be found on the Company’s website at www.admabiologics.com.

Additional Important Safety Information about Nabi-HB

^®

Individuals known to have had an anaphylactic or severe systemic reaction to human globulin should not receive Nabi-HB^® [Hepatitis B Immune Globulin (Human)] or any other human immune globulin. Individuals who are deficient in IgA have the potential to develop antibodies against IgA and anaphylactic reactions. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, Nabi-HB should be given only if the expected benefits outweigh the potential risks. Nabi-HB is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents (e.g., viruses) and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Nabi-HB [Hepatitis B Immune Globulin (Human)], must be administered only intramuscularly for post-exposure prophylaxis. Vaccination with live virus vaccines (e.g., MMR) should be deferred until approximately three months after administration of Nabi-HB. The most common adverse reactions associated with Nabi-HB in clinical trials were erythema and ache at the injection site as well as systemic reactions such as headache, myalgia, malaise, nausea and vomiting. No anaphylactic reactions with Nabi-HB have been reported. Please see the full Prescribing Information for Nabi-HB [Hepatitis B Immune Globulin (Human)].

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

Warnings and Precautions:

In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, Nabi-HB, Hepatitis B Immune Globulin (Human), should be given only if the expected benefits outweigh the potential risks. Nabi-HB is made from human plasma. Products made from human plasma may contain infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products can transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current viral infections, and by inactivating and/or reducing certain viruses. The Nabi-HB manufacturing process includes a solvent/detergent treatment step (using tri-n-butyl phosphate and Triton^® X-100) that is effective in inactivating known enveloped viruses such as HBV, HCV, and HIV. Nabi-HB is filtered using a Planova^® 35 nm Virus Filter that is effective in reducing the levels of some enveloped and non enveloped viruses. These two processes are designed to increase product safety. Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products. ALL infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other health care provider to Biotest Pharmaceuticals at 1-800-458-4244. The physician should discuss the risks and benefits of this product with the patient.

Nabi-HB, Hepatitis B Immune Globulin (Human), must be administered only intramuscularly for post-exposure prophylaxis. The preferred sites for intramuscular injections are the anterolateral aspect of the upper thigh and the deltoid muscle. If the buttock is used due to the volume to be injected, the central region should be avoided; only the upper, outer quadrant should be used, and the needle should be directed anterior (i.e., not inferior or perpendicular to the skin) to minimize the possibility of involvement with the sciatic nerve22. The 50 healthy volunteers who received Nabi-HB in pharmacokinetic studies were followed for 84 days for possible development of anti-HCV antibodies. No subject seroconverted.

Drug Interactions
Vaccination with live virus vaccines should be deferred until approximately three months after administration of Nabi-HB, Hepatitis B Immune Globulin (Human). It may be necessary to revaccinate persons who received Nabi-HB shortly after live virus vaccination. There are no available data on concomitant use of Nabi-HB and other drugs; therefore, NabiHB should not be mixed with other drugs.

Pregnancy Category C
Animal reproduction studies have not been conducted with Nabi-HB. It is also not known whether Nabi-HB can cause fetal harm when administered to a pregnant woman or can affect a woman’s ability to conceive. Nabi-HB should be given to a pregnant woman only if clearly indicated.

Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Nabi-HB is administered to a nursing mother.

Pediatric Use
Safety and effectiveness in the pediatric population have not been established for Nabi-HB. However, the safety and effectiveness of similar hepatitis B immune globulins have been demonstrated in infants and children.

Geriatric Use
Clinical studies of Nabi-HB did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

Adverse Reactions:
Fifty male and female volunteers received Nabi-HB, Hepatitis B Immune Globulin (Human), intramuscularly in pharmacokinetics trials20. The number of patients with reactions related to the administration of Nabi-HB included local reactions such as erythema 6 (12%) and ache 2 (4%) at the injection site, as well as systemic reactions such as headache 7 (14%), myalgia 5 (10%), malaise 3 (6%), nausea 2 (4%), and vomiting 1 (2%). The majority (92%) of reactions were reported as mild. The following adverse events were reported in the pharmacokinetics trials and were considered probably related to Nabi-HB: elevated alkaline phosphatase 2 (4%), ecchymosis 1 (2%), joint stiffness 1 (2%), elevated AST 1 (2%), decreased WBC 1 (2%), and elevated creatinine 1 (2%). All adverse events were mild in intensity. There were no serious adverse events. No anaphylactic reactions with Nabi-HB have been reported. However, these reactions, although rare, have been reported following the injection of human immune globulins.

About ADMA Biologics, Inc.

ADMA Biologics is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM^® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB^® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

COMPANY CONTACT:

Skyler Bloom
Director, Investor Relations and Corporate Strategy | 201-478-5552 | [email protected]

INVESTOR RELATIONS CONTACT:

Sam Martin
Managing Director, Argot Partners | 212-600-1902 | [email protected]

 

CINCINNATI, April 13, 2021 (GLOBE NEWSWIRE) — In 2000, Chris Cicchinelli was twenty-five and at a crossroads. He had just accepted a promising sales job where he would be spending half the year in Italy when his mother, Patty Brisben, called. She wanted her son’s help in growing her women-only, in-home and virtual party business featuring intimacy and wellness products.

Cicchinelli had been earning well over $100,000 annually at his previous job. Patty said she could pay him just $22,000. Still, he said yes, planning to stay just a few months to get the company—which would soon be rechristened as Pure Romance—on its feet. But after recognizing its potential, he never left.

Long hours on the road and a restyled business model initially led to financial struggles, and more questions than answers. But their strategy ultimately paid off in explosive growth that swelled the company’s revenues from $3 million in 2001 to more than $350 million today. Its workforce of independent ambassadors now approaches 40,000 in the U.S. and abroad, despite the recent challenges posed by the COVID-19 pandemic.

In “The Secret is You,” author Chris Cicchinelli charts his two-decade journey transforming Pure Romance into the world’s largest in-home/virtual party company of its kind, while also sharing his innovative approach for helping women become successful entrepreneurs themselves. This book is a game-plan for anyone looking for personal or professional growth and to live their life by design.

Chris Cicchinelli is the CEO of the Cincinnati-based Pure Romance, LLC, where he leads business development, operations, sales, and marketing. He is also the founder, along with his wife, Jessica, of the Living with Change Foundation—a nonprofit dedicated to supporting transgender youth and their families.

“The Secret is You” is now available for purchase at Secretisyou.com.

Contact: Jackie Reau
Game Day
(513) 708-5822
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d4b5e1c4-2d0e-417b-9878-82fca39a10fb

ALBUQUERQUE, N.M., April 13, 2021 (GLOBE NEWSWIRE) — Array Technologies (NASDAQ: ARRY) (“Array”), a leading provider of tracker solutions and services for utility-scale solar energy projects, today announced it has obtained ISO 9001:2015 certification from DQS Inc. as of January 22, 2021.

“We are proud of our commitment to producing products of the highest quality,” said Stuart Bolland, Chief Operations Office at Array Technologies. “Customer satisfaction is at the center of everything we do and this ISO certification assures our customers that we continue to prioritize robust quality, reliability and durability in our manufacturing and management system  processes today and in the future.”

ISO 9001 quality management system standards are designed to help organizations ensure they address the needs of customers and stakeholders while meeting statutory and regulatory requirements related to a product or service. ISO 9001 examines the fundamentals of quality management systems, including seven quality management principles.

“Array Technologies has demonstrated their commitment to quality and focus on meeting customer needs by successfully completing the rigorous ISO 9001:2015 initial audit process and achieving certification” says Lisa Brandon, Vice President of Business Development at DQS Inc.

Array has established itself as a true authority in utility-scale solar solutions with a more than 30-year track record of designing and manufacturing solar trackers which are deployed around the globe.

About Array Technologies, Inc.

Array Technologies (NASDAQ: ARRY) is a leading global technology company providing tracker solutions and services for utility-scale solar energy projects as one of the world’s largest manufacturers of ground-mounted systems. With efficient installation and terrain flexibility coupled with high reliability, durability, and performance, Array delivers a lower levelized cost of energy. The Company’s focus on innovation, combined with its customer-centric approach, has helped achieve some of the industry’s best returns. Array Technologies is headquartered in the United States with offices in Europe, Central America, and Australia. Contact us at arraytechinc.com or view our LinkedIn page.

About DQS Inc.

DQS Inc. was formed as a strategic partnership between Underwriters Laboratories (UL) and DQS (Germany’s first certification body). As a result of this merger, DQS Inc. is able to provide global resources and highly skilled, local auditors. The assessment and certification of management systems is our core business. With over 60,000 certificates in 100 countries, we serve a wide spectrum of industry sectors, including automotive, electrical engineering, engine construction, the metal and chemicals industries, services, food, health care, the aviation and aerospace industries and telecommunications.

Forward Looking Statements

This press release contains forward looking statements. These statements are not historical facts but rather are based on the Company’s current expectations and projections regarding its business, operations and other factors relating thereto. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates” and similar expressions are used to identify these forward looking statements. These statements are only predictions and as such are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual results may differ materially from those in the forward looking statements as a result of a number of factors.

Media Contact:

James McCusker
203-585-4750
[email protected]  

Investor Relations Contact:
505-437-0010
[email protected]

Transaction Includes Establishment of Revolving Line of Credit

SAN FRANCISCO, CA, April 13, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced the signing of a $22 million credit agreement with Fifth Third Bank, N.A., the principal subsidiary of Fifth Third Bancorp, a diversified bank holding company headquartered in Cincinnati, Ohio, with over $200 billion in assets.

The Company’s $22 million credit agreement with Fifth Third Bank, which closed on Friday April 9^th, 2021, is composed of three loan facilities.  A term loan of $9.5 million will refinance $6.8 million of domestic Gamma Knife debt, $1.6 million will primarily be used for two Gamma Knife reloads with two customers that have recently extended their agreements, and the remaining $1.1 million will be available for future projects. A second term loan of $5.5 million will refinance the Company’s PBRT Orlando equipment debt as well as provide additional working capital. Together, these term loans will deliver significant interest expense and principal payment reductions and result in increased cash generation for the Company.  The third facility of the credit agreement provides for a $7.0 million revolving line of credit which will be used to increase the Company’s flexibility in negotiating future projects and also be available for general corporate purposes.

Ray Stachowiak, Chief Executive Officer of AMS, commented, “This milestone transaction with Fifth Third Bank will enable AMS to realize substantial savings from the refinancing of our existing debt, and at the same time, provide us with incremental capital to accelerate the growth of our business. The transaction immediately lowers our cost of capital and provides ample financial resources to increase our capacity for additional projects through a more diversified business model. This includes broadening our product offerings and further expanding domestically and internationally with both wholesale and retail financing solutions. These actions, together with the new banking relationship with Fifth Third Bank, are key parts of our strategic plan to provide AMS with a path to increased growth and sustained profitability.”

About American Shared Hospital Services (NYSE American: AMS)

American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. AMS is a world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia (facial pain). The Company also offers proton therapy, and the latest IGRT, IMRT and MR/LINAC systems. For more information, please visit: www.ashs.com.

Safe Harbor Statement

This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services (including statements regarding the expected continued growth of the Company and the expansion of the Company’s Gamma Knife, proton therapy and MR/LINAC business, which involve risks and uncertainties including, but not limited to, the risks of economic and market conditions, the risks of variability of financial results between quarters, the risks of the Gamma Knife and proton therapy businesses, the risks of changes to Medicare reimbursement rates or reimbursement methodology, the risks of the timing, financing, and operations of the Company’s Gamma Knife and proton therapy businesses, the risks of the COVID-19 pandemic and its effect on the Company’s business operations and financial condition, the risk of expanding within or into new markets, the risk that the integration or continued operation of acquired businesses could adversely affect financial results and the risk that current and future acquisitions may negatively affect the Company’s financial position. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and the definitive Proxy Statement for the Annual Meeting of Shareholders that was held on June 26, 2020.

Contacts:

American Shared Hospital Services
Ray Stachowiak
Chief Executive Officer
[email protected]

Investor Relations
Stephanie Prince
PCG Advisory
P: (646) 863-6341
[email protected]

Parsippany, New Jersey, USA, April 13, 2021 (GLOBE NEWSWIRE) — Wireless Telecom Group (NYSE American: WTT), announced that Noisecom has introduced the UFX7000B, strengthening its leadership in noise generation solutions with this new version of its most versatile and most popular programmable noise generator. Built upon core Noisecom technology, the UFX7000B features a new design and streamlined user interface in an innovative platform, which will serve as the building block for a broad range of customizable, configurable, and specialized solutions. The unique noise generation products enabled by UFX7000B are vital to address the complex demands of growing and emerging wireless applications, including GPS, satellite communications, aerospace, defense, and wireless communications such as next-generation Wi-Fi and 5G systems, up to 40 GHz.

“The UFX platform has been our most popular instrument for many years. Our customers appreciate the broad range of capabilities that include signal combining, filtering, attenuation, and switching,” said Dr. Lee McMillan, VP, Engineering and Manufacturing at Wireless Telecom Group. “With the new UFX7000B product we have an advanced platform to build upon for the future of all our benchtop and rackmount programable noise generators so we can better meet application- and industry-specific needs.”

The Noisecom UFX7000B broadband additive white Gaussian noise (AWGN) generator has a powerful single board computer with flexible architecture used to create complex custom noise signals for advanced test systems. This versatile platform allows the user to meet their most challenging design requirements. Precision components provide high output power with superior flatness, and the flexible computer architecture allows control of multiple attenuators, switches, and filter banks. Joining a robust portfolio of leading benchtop noise generators, the newly designed Noisecom UFX7000B demonstrates a continued innovation in generating, controlling, and using RF and microwave noise to support high-performance wireless applications.

– END –

About Wireless Telecom Group

Wireless Telecom Group, Inc., comprised of Boonton, CommAgility, Holzworth, Microlab, and Noisecom, is a global designer and manufacturer of advanced RF and microwave components, modules, systems, and instruments. Serving the wireless, telecommunication, satellite, military, aerospace, semiconductor, and medical industries, Wireless Telecom Group products enable innovation across existing and emerging wireless technologies. With a product portfolio including peak power meters, signal generators, phase noise analyzers, signal processing modules, LTE PHY/stack software, power splitters and combiners, GPS repeaters, public safety components, noise sources, and programmable noise generators, Wireless Telecom Group supports the development, testing, and deployment of wireless technologies around the globe.

Wireless Telecom Group, Inc.’s website address is wirelesstelecomgroup.com. Except for historical information, the matters discussed in this news release may be considered “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief, or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. Such risks and uncertainties are identified in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2020.

Investor Contact

Andrew M. Berger
Managing Director
SM Berger& Company
(216) 464-6400
[email protected]

Marketing Contact

Maria Droge: +1 (973) 386-9696
Wireless Telecom Group Inc.
25 Eastmans Road
Parsippany, NJ 07054
Tel: (973) 386-9696
Fax: (973) 386-9191
www.wtcom.com 

MISSION, Kan., April 13, 2021 (GLOBE NEWSWIRE) — Xact Data Discovery (XDD), a leading international provider of eDiscovery, data management and managed review services for law firms and corporations, announces the acquisition of Zeledon-Castillo, LLC’s eDiscovery assets. Based in San Antonio, TX, Zeledon-Castillo provides core eDiscovery services to key clients, including a Fortune 500 financial services company, in the southern Texas region.

David Moran, XDD President and COO, states, “As we continue to expand business operations in the southwest, adding Zeledon-Castillo’s eDiscovery staff, resources and key clients they serve in the San Antonio, TX region was a natural fit. Similar to XDD’s commitment to providing exemplary customer service, Jorge and the Zeledon-Castillo eDiscovery team will further strengthen our service capabilities in this growing market.”    

Jorge Zeledon-Castillo, CEO at Zeledon-Castillo, states, “Joining forces with XDD further empowers our ability to provide advanced eDiscovery and litigation support services to our clients in southern Texas. XDD’s reputation for instilling optimized processes and communication are second to none. Coupled with their advanced technologies, we look forward to integrating our people and clients into the XDD ecosystem.”

About Xact Data Discovery

Xact Data Discovery is a leading international provider of eDiscovery, data management and managed review services for law firms and corporations. XDD helps clients optimize their eDiscovery matters by orchestrating precision communication between people, processes, technology and data.  

XDD services include forensics, eDiscovery processing, Relativity hosting and managed review. XDD has 21 offices throughout the United States, two locations in India and one in the UK. XDD provides exceptional customer service with a commitment to responsive, transparent and timely communication to ensure clients remain informed throughout the entire discovery life cycle.

Press Contact:
Bob Lorum
Xact Data Discovery
951.378.1991
[email protected]

About Zeledon-Castillo, LLC

Zeledon-Castillo, LLC is a full-service litigation support company based in San Antonio, TX. As a full-service Litigation Support Company, with over 20 years of experience, we work with our clients to reduce the cost of legal discovery by helping them understand the tools and technologies available for the collection, analysis, and production of discoverable information. Zeledon-Castillo supports all major eDiscovery platforms and offers top notch online review and production tools for any sized case.

 

PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) — Location identity company Incognia today announced the publication of their second Mobile App Report, which unveils results from their recent Mobile App Friction Study on mCommerce Checkout. The study was conducted to provide retail companies with mobile apps insights on the state of friction during mCommerce checkout, which can help strengthen customer satisfaction and retention. Mobile apps from major retailers and specialty retailers were reviewed, and included Target, Walmart, Costco, BestBuy, Home Depot, Lowe’s, Sephora, Ulta Beauty, Bed, Bath & Beyond, Wayfair, JOANN, and Hobby Lobby.

The transformation of buying behavior is one of the biggest changes to come out of the global pandemic, with mCommerce continuing to gain ground. The latest Incognia Mobile App Friction Report analyzes the purchasing experience of twelve of the most popular mCommerce apps by ranking the checkout friction and reviewing the types of mobile purchase options supported by the app, including pickup, delivery, and payment options.

To adjust to the dramatic shift in buyer behavior, retailers have quickly responded by enhancing their mobile apps, offering consumers an expanded choice of payment and purchase options. Two out of three retail mobile apps studied in the Mobile App Friction Report now offer BOPIS options to accommodate changes in consumer behavior. In addition, the study showed strong adoption of PayPal as an in-app payment option, with over 80% of the retail apps reviewed in the study supporting PayPal, compared to Apple Pay which is supported by 20% of the apps reviewed in the study.

For each app, the Mobile App Report examines and quantifies factors that contribute to friction during the mCommerce checkout experience. Results from the Mobile App Checkout Friction Study indicate that Lowe’s, Bed, Bath & Beyond, and Home Depot had the lowest Checkout Friction Index for pickup purchases. Sephora, Lowe’s, and Home Depot had the lowest Checkout Friction Index scores for delivery purchases.

“The pandemic caused an influx of consumers to shop on their mobile phones, and top retailers responded by investing in their mCommerce apps. For retailers, the purchasing experience is critical to the customer experience,” said André Ferraz, founder and CEO of Incognia. “The level of checkout friction can easily make or break customer satisfaction and retention, and our latest Mobile App Report clearly outlines which areas of the mCommerce experience adds friction for the users.”

The data gathered during the analysis of each app was used to create the Incognia Checkout Friction Index. The lower the Index, the better the purchasing experience. The Incognia Checkout Friction Index accounts for the following factors:

• Application Time: The time required to complete a purchase via the mobile app, including the time from the first registration screen to the last, where the purchase is submitted and completed. The checkout time of each app is shown as the average of the checkout time recorded on both operating systems, Android and iOS.
• Screens: The number of screens that are presented during the purchasing process was recorded for each app, including all the screens from the beginning until payment submission.
• Clicks: The number of clicks required to complete a purchase were counted. If any screen required multiple clicks, all were included in the total count.
• Fields: All fields and checkboxes required as part of the purchase process were counted and included in the count of required fields.
• Payment Options: The specific payment options offered to the user as part of the purchasing experience were recorded.
• Purchase Options: The choice of purchase options including pick up in-store or curbside, and same-day and extended delivery options were recorded.

Key data points from the report include:

• Lowest mCommerce Checkout Friction (pickup purchase): Lowe’s, Bed, Bath & Beyond and Home Depot.
• Lowest mCommerce Checkout Friction (delivery purchase): Sephora, Lowe’s and Home Depot.
• 4 minutes: Average time to complete the checkout process for pickup orders. JOANN had the shortest purchase time at 2:41 minutes.
• 3.5 minutes: Average time to complete the checkout process for delivery orders. Hobby Lobby had the shortest purchase time at 2:36 minutes.
• 12 fields: Average number of fields required for pickup and delivery orders. Lowe’s and Sephora tied for the fewest number of required fields at 3 total.
• 25 clicks: Average number of clicks required for pickup orders. Lowe’s required the least amount of clicks to checkout at 16 total.
• 22 clicks: Average number of clicks required for delivery orders. Sephora had the least amount of clicks to checkout at 9 total.

Download the Incognia Mobile App Friction Report here: https://www.incognia.com/resources/retail-checkout-friction-index

About Incognia

Incognia is a location identity company that enables advanced mobile fraud prevention for banks, fintech and mCommerce companies. Using location behavioral biometrics Incognia offers frictionless identity verification and authentication. Incognia’s location technology uses network signals and on-device sensors to deliver highly precise location information. By building an anonymous location behavioral pattern, unique for each user, Incognia creates a private digital identity for account security.

Incognia is privately held and headquartered in Palo Alto, California with teams in New York and Brazil.

Stay connected and follow Incognia on Twitter and LinkedIn.

Media Contact

Madeline Kalicka, Karbo Communications for Incognia
(240) 427-8961
[email protected]

Move to larger facility along with recent key hires illustrates Company’s continued commitment to scaling production as it continues to push forward with uplisting process to a U.S. senior exchange

SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) — KULR Technology Group Inc. (OTCQB: KULR) (the “Company” or “KULR”), a leading developer of next-generation thermal management technologies, today announced it is expanding its manufacturing presence to a new, larger facility in San Diego, CA to accommodate continued business growth.

KULR plans to leverage its new facility to commence commercialization of its product portfolio while also establishing new internal operational efficiencies. The new facility will also provide KULR’s partners with improved work space to facilitate collaboration and communication while providing the Company with further room for growth.

“We’re truly happy to be able to move into a new building with significantly more production space while remaining in our home city of San Diego,” said Keith Cochran, President and COO of KULR Technology Group. “More than anything, this move and recent key hires represent our continued commitment to scale and commercialization of KULR’s space-proven thermal management technologies. This strategic move will assist the Company as it pushes forward with the uplisting process to a U.S. senior exchange.”

As of May 1, 2021, KULR’s new location will be based at the McGrath Commerce Center, 4863 Shawline Street, Suite B, San Diego, CA 92111.

About KULR Technology Group Inc.

KULR Technology Group Inc. (OTCQB: KULR) develops, manufactures and licenses next-generation carbon fiber thermal management technologies for batteries and electronic systems. Leveraging the company’s roots in developing breakthrough cooling solutions for NASA space missions and backed by a strong intellectual property portfolio, KULR enables leading aerospace, electronics, energy storage, 5G infrastructure, and electric vehicle manufacturers to make their products cooler, lighter and safer for the consumer. For more information, please visit www.KULRTechnology.com.

Safe Harbor Statement

This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. This release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on May 14, 2020. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. All forecasts are provided by management in this release are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely on management’s best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise. 

Media Contact:

Derek Newton
Head, Media Relations
Main: (786) 499-8998
[email protected]

Investor Relations:

KULR Technology Group Inc.
Main: (888) 367-5559
[email protected]